QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=9CADF17AD417DE0F63F1F35F635CB0D4;jsessionid=44CBA49F116AD1B9D96D511110636BBB;jsessionid=1666F696187E44A37E9E348D8C8D916F;jsessionid=8EA2AC59EB514A25D03FB6212541471C;jsessionid=5BD143653D897F01683B8D330E88CB2F;jsessionid=DEB26BD9644B68FBC3B9A88CA20B13F0 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=9CADF17AD417DE0F63F1F35F635CB0D4;jsessionid=44CBA49F116AD1B9D96D511110636BBB;jsessionid=1666F696187E44A37E9E348D8C8D916F;jsessionid=8EA2AC59EB514A25D03FB6212541471C;jsessionid=5BD143653D897F01683B8D330E88CB2F;jsessionid=DEB26BD9644B68FBC3B9A88CA20B13F0